Neurelis, a San Diego-based specialty pharmaceutical company, finalized a Series A financing round.
The round was led by LYZZ Capital.
The company intends to use the funds to advance its lead program, NRL-1 (intranasal diazepam), through the remaining clinical work in preparation for FDA submission of a New Drug Application (NDA) in the US.
Led by Craig C. Chambliss, President and Chief Executive Officer, Neurelis is a specialty pharmaceutical company focused on the treatment of central nervous system disorders.
NRL-1 (intranasal diazepam) is a proprietary formulation of diazepam, delivered via a nasal formulation in a spray, being developed for the management of pediatric and adult patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity, also known as cluster seizures.
It has been granted Orphan Drug Designation by the FDA.